Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO.

Biotechnology

Outlook Therapeutics

Outlook Therapeutics' headquarters in Woodbridge Township, NJ, United States

Lawrence A. Kenyon

Terry Dagnon

Jennifer Kissner

Surendra Sharma

Glen Olsheim

Dan Courtney

Joseph Manhede CA, CPA, MBA

Elaine Ludovico (Sirmans)

Joel Prieve

Christopher Yonan

Entisar Dahan, MPM, PHR

Lauren Nelson

Pamela Monterola

George Bitar

Kathleen Billman

Tony Moses

Alison Oliver

Gerd Auffarth

Andong Huang

Randy Thurman

Faisal G. Sukhtian

Kurt J. Hilzinger

Julian Gangolli

Yezan Haddadin

Description

People (6)

Entisar Dahan, MPM, PHR

Surendra Sharma

Elaine Ludovico (Sirmans)

Joseph Manhede CA, CPA, MBA

Tyler Collins

Dan Courtney

Jobs